CONCLUSIONS
The evaluation of parameters that determine the deficiency or subclinical levels of vitamin B[SUB]12[/SUB] deficiency can be an ally in treating patients affected by COVID-19 or in persistent symptoms of the disease, given the important functions of this vitamin in the skeletal muscle–gut–brain axis.
Vitamin B[SUB]12[/SUB] plays an important role in viral infections. The consumption of a healthy diet containing vitamin B[SUB]12[/SUB] sources, and especially supplementation with methylcobalamin and cyanocobalamin, are promising alternatives as adjuvants in the treatment of COVID-19, especially in patients with B[SUB]12[/SUB] deficiency or deficiency risk. However, establishing doses, intervention times, and mechanisms of action of vitamin B[SUB]12[/SUB] against COVID-19 can be a great challenge.
Researchers are encouraged to identify whether the subclinical deficiency or deficiency itself of this vitamin is a risk factor for COVID-19 complications, and it is necessary to carry out intervention studies with vitamin B[SUB]12[/SUB] supplementation in both the adjuvant treatment of mild, moderate, and severe COVID-19 and post–COVID-19, with a focus on minimizing symptoms related to the muscle–gut–brain axis.
